• Enabling the possibility for a universal
    bone marrow transplant solution for patients
    with cancers and rare genetic diseases

  • Pioneering

  • Novel cellular and
    immune therapeutics

Latest Updates

Jun 2018
Jun 18, 2018

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Read More >
Jul 2018
Jul 17, 2018

Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation

Read More >
Apr 2018
Apr 30, 2018

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Read More >
Apr 2018
Apr 26, 2018

Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

Read More >

Gamida Cell is committed to changing the treatment paradigm for patients with cancer and rare genetic diseases.

One Technology:
Many Applications

Gamida Cell’s world-class scientists have developed a technology that offers the potential of curative cellular and immune therapeutics for a diverse population of patients in need. The proprietary NAM technology, which harnesses epigenetics to increase the population of functional cells in culture, is utilized to develop a broad pipeline of best-in-class therapies to treat cancer and rare genetic diseases.

Innovative Treatments

  • NiCord®


    A Curative Treatment for High-Risk Blood Cancers

  • CordIn™


    A Curative Treatment for Rare Genetic Diseases

  • NAM-NK Cells

    NAM-NK Cells

    An immunotherapy for Blood Cancers and Solid Tumors